vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and ULTRALIFE CORP (ULBI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $48.5M, roughly 1.6× ULTRALIFE CORP). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 10.6%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $607.0K). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 7.5%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Ultralife Corporation designs and manufactures batteries and communications systems worldwide. Ultralife serves government and defense, medical, safety and security, energy, robotics and other customers across the globe through the design and development of a range of products. Founded in 1991 when launched as an Initial Public Offering (IPO) evolving from Kodak’s Ultra Technologies battery division, and headquartered in Newark, New York, the Company’s business segments include battery and en...

PBYI vs ULBI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.6× larger
PBYI
$75.5M
$48.5M
ULBI
Growing faster (revenue YoY)
PBYI
PBYI
+17.2% gap
PBYI
27.7%
10.6%
ULBI
More free cash flow
PBYI
PBYI
$13.8M more FCF
PBYI
$14.4M
$607.0K
ULBI
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
7.5%
ULBI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PBYI
PBYI
ULBI
ULBI
Revenue
$75.5M
$48.5M
Net Profit
$-7.4M
Gross Margin
69.3%
24.9%
Operating Margin
22.7%
-21.9%
Net Margin
-15.3%
Revenue YoY
27.7%
10.6%
Net Profit YoY
-3925.8%
EPS (diluted)
$0.26
$-35.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
ULBI
ULBI
Q4 25
$75.5M
$48.5M
Q3 25
$54.5M
$43.4M
Q2 25
$52.4M
$48.6M
Q1 25
$46.0M
$50.7M
Q4 24
$59.1M
$43.9M
Q3 24
$80.5M
$35.7M
Q2 24
$47.1M
$43.0M
Q1 24
$43.8M
$41.9M
Net Profit
PBYI
PBYI
ULBI
ULBI
Q4 25
$-7.4M
Q3 25
$8.8M
$-1.2M
Q2 25
$5.9M
$879.0K
Q1 25
$3.0M
$1.9M
Q4 24
$194.0K
Q3 24
$20.3M
$258.0K
Q2 24
$-4.5M
$3.0M
Q1 24
$-4.8M
$2.9M
Gross Margin
PBYI
PBYI
ULBI
ULBI
Q4 25
69.3%
24.9%
Q3 25
77.7%
22.2%
Q2 25
76.5%
23.9%
Q1 25
77.1%
25.1%
Q4 24
76.4%
24.2%
Q3 24
63.9%
24.3%
Q2 24
77.4%
26.9%
Q1 24
75.5%
27.4%
Operating Margin
PBYI
PBYI
ULBI
ULBI
Q4 25
22.7%
-21.9%
Q3 25
17.6%
-2.2%
Q2 25
12.7%
4.6%
Q1 25
8.7%
6.7%
Q4 24
22.6%
3.4%
Q3 24
27.4%
1.4%
Q2 24
-4.6%
9.1%
Q1 24
-5.3%
9.7%
Net Margin
PBYI
PBYI
ULBI
ULBI
Q4 25
-15.3%
Q3 25
16.2%
-2.8%
Q2 25
11.2%
1.8%
Q1 25
6.5%
3.7%
Q4 24
0.4%
Q3 24
25.2%
0.7%
Q2 24
-9.6%
6.9%
Q1 24
-11.0%
6.9%
EPS (diluted)
PBYI
PBYI
ULBI
ULBI
Q4 25
$0.26
$-35.00
Q3 25
$0.17
$-0.07
Q2 25
$0.12
$0.05
Q1 25
$0.06
$0.02
Q4 24
$0.40
$37.72
Q3 24
$0.41
$0.02
Q2 24
$-0.09
$0.18
Q1 24
$-0.10
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
ULBI
ULBI
Cash + ST InvestmentsLiquidity on hand
$97.5M
$9.3M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
$130.0M
Total Assets
$216.3M
$216.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
ULBI
ULBI
Q4 25
$97.5M
$9.3M
Q3 25
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
$6.9M
Q3 24
$96.7M
$6.8M
Q2 24
$96.8M
$6.7M
Q1 24
$107.2M
$10.1M
Total Debt
PBYI
PBYI
ULBI
ULBI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
$55.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
PBYI
PBYI
ULBI
ULBI
Q4 25
$130.3M
$130.0M
Q3 25
$115.3M
$137.3M
Q2 25
$104.7M
$138.4M
Q1 25
$97.1M
$136.4M
Q4 24
$92.1M
$134.0M
Q3 24
$71.1M
$134.5M
Q2 24
$48.5M
$133.2M
Q1 24
$51.0M
$128.8M
Total Assets
PBYI
PBYI
ULBI
ULBI
Q4 25
$216.3M
$216.9M
Q3 25
$202.9M
$222.2M
Q2 25
$194.9M
$221.0M
Q1 25
$196.2M
$223.8M
Q4 24
$213.3M
$220.5M
Q3 24
$220.7M
$172.4M
Q2 24
$205.0M
$169.8M
Q1 24
$214.1M
$180.6M
Debt / Equity
PBYI
PBYI
ULBI
ULBI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
0.41×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
ULBI
ULBI
Operating Cash FlowLast quarter
$14.4M
$1.5M
Free Cash FlowOCF − Capex
$14.4M
$607.0K
FCF MarginFCF / Revenue
19.1%
1.3%
Capex IntensityCapex / Revenue
0.0%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$7.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
ULBI
ULBI
Q4 25
$14.4M
$1.5M
Q3 25
$9.7M
$198.0K
Q2 25
$14.1M
$5.9M
Q1 25
$3.6M
$3.4M
Q4 24
$15.6M
$3.0M
Q3 24
$11.0M
$4.7M
Q2 24
$1.0M
$8.9M
Q1 24
$11.2M
$-81.0K
Free Cash Flow
PBYI
PBYI
ULBI
ULBI
Q4 25
$14.4M
$607.0K
Q3 25
$9.7M
$-797.0K
Q2 25
$14.1M
$4.8M
Q1 25
$3.6M
$2.5M
Q4 24
$15.6M
$2.4M
Q3 24
$11.0M
$4.2M
Q2 24
$1.0M
$8.6M
Q1 24
$-453.0K
FCF Margin
PBYI
PBYI
ULBI
ULBI
Q4 25
19.1%
1.3%
Q3 25
17.7%
-1.8%
Q2 25
26.8%
10.0%
Q1 25
7.7%
4.9%
Q4 24
26.4%
5.6%
Q3 24
13.7%
11.6%
Q2 24
2.1%
19.9%
Q1 24
-1.1%
Capex Intensity
PBYI
PBYI
ULBI
ULBI
Q4 25
0.0%
1.8%
Q3 25
0.0%
2.3%
Q2 25
0.0%
2.3%
Q1 25
0.1%
1.8%
Q4 24
0.0%
1.4%
Q3 24
0.0%
1.7%
Q2 24
0.0%
0.8%
Q1 24
0.0%
0.9%
Cash Conversion
PBYI
PBYI
ULBI
ULBI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
6.75×
Q1 25
1.21×
1.81×
Q4 24
15.70×
Q3 24
0.54×
18.40×
Q2 24
3.01×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PBYI
PBYI

Segment breakdown not available.

ULBI
ULBI

Commercial$36.3M75%
Government Defense$9.6M20%
Communications Systems Segment$2.6M5%

Related Comparisons